Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2020-09-16 Declaration of Voting R…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '임시주주총회결과' (Extraordinary General Meeting Results) and details the voting outcomes for specific agenda items (director appointments, auditor appointment, and stock option approval) held on 2020-09-16. This falls directly under the definition of a Declaration of Voting Results.
2020-09-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report) for a previously submitted filing. It details changes to stock option grants, including adjustments to the number of shares and the list of recipients. This type of disclosure regarding stock-based compensation and capital structure changes falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the financial authorities (Financial Services Commission/Korea Exchange).
2020-09-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly labeled as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of recipients, share counts, and fair value calculations. This type of filing is a standard regulatory disclosure regarding capital structure and employee compensation instruments, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for capital changes).
2020-09-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly identified as a '정정신고' (Correction Report). It details changes to previously reported stock option grants, including adjustments to the number of shares, the list of recipients, and the responsible officer. This type of filing is a standard corporate disclosure regarding capital structure and equity-based compensation, which falls under the category of Share Issue/Capital Change (SHA) as it relates to the issuance of stock options.
2020-09-16 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Gencurix) announcing a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). This is a standard material event disclosure required by the Korea Exchange (KRX) for significant contracts. Since it does not fit into specific categories like M&A, dividends, or share repurchases, it falls under the general regulatory filing category.
2020-09-04 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Extraordinary General Meeting of Shareholders' (주주총회소집공고) for Gencurix. It details the meeting date, location, agenda items (election of directors and auditors, stock option grants), and information regarding electronic voting. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their votes, which falls under the Proxy Solicitation & Information Statement category.
2020-09-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.